- Trial phase
- Phase 1/2a
- Time to market
- Given that ACCG-2671 is still in Phase 1/2a, potential approval is likely many years away (probably 2029-2031 at the earliest), assuming successful clinical development.
- Why 4/10
- The next hard, dated catalyst is the multiple-ascending-dose (MAD) data from the Phase 1/2a trial, expected in the first half of 2027 (1H 2027), which is more than 6 months away. ACCG-2671 is an early-stage asset at a company whose lead program is aleniglipron (Phase 3), so this drug is not the primary value driver.
ACCG-2671 is a very early-stage (Phase 1/2a) oral amylin receptor agonist for obesity. The single-dose data from September 2026 showed a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is the MAD (multiple ascending dose) data expected in 1H 2027, which will show whether the weight-loss signal persists with repeat dosing. Investors should watch for whether the MAD data confirms a competitive profile versus other oral amylin agonists in development at Novo Nordisk and others.
Price Chart
Executive Summary
ACCG-2671 is an early-stage, oral small-molecule dual amylin and calcitonin receptor agonist (DACRA) being developed by Structure Therapeutics (GPCR) for obesity and metabolic conditions. In September 2026, the company reported positive Phase 1/2a single-dose data showing a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is multiple-ascending-dose data expected in the first half of 2027. ACCG-2671 is a secondary pipeline asset behind Structure's lead program, aleniglipron (an oral GLP-1 receptor agonist now in Phase 3). The stock trades near $21, down sharply from its 52-week high of $95, with a strong-buy analyst consensus and a mean price target of ~$104 implying ~380% upside, though this reflects the broader pipeline rather than ACCG-2671 alone.
How It Works
ACCG-2671 is an oral (pill) small molecule that activates the amylin and calcitonin receptors. Amylin is a hormone that works alongside GLP-1 to signal fullness and reduce food intake. Unlike injectable weight-loss drugs, this one is taken by mouth. It is a dual amylin and calcitonin receptor agonist (DACRA).
Trial Status
A Phase 1/2a single ascending dose (SAD) study in 31 healthy adults without obesity completed and reported positive topline data on September 8, 2026. A multiple ascending dose (MAD) portion is ongoing, with data expected in the first half of 2027.
The Two-Sided Case
Upcoming Catalysts
- MAD (multiple ascending dose) data from the Phase 1/2a trial expected in 1H 2027.
- Aleniglipron (lead program) Phase 3 ACCOMPLISH program data readouts, which could indirectly affect sentiment for ACCG-2671 as part of the same pipeline.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Structure Therapeutics Inc. PRESS-RELEASE GPCR ·Originating report